UNIVERSITY OF WISCONSIN-MADISON

University of Wisconsin-Madison researchers have developed personalized cancer vaccines using pyroptotic vesicles, tiny sacs from dying cancer cells, that significantly extended survival in mouse models of triple-negative breast cancer and melanoma.

Seer's new Proteograph ONE Assay and SP200 Automation Instrument can process over 1,000 samples per week, doubling throughput while reducing per-sample costs by approximately 60% compared to 2021.

Archeus Technologies and Wisconsin Alumni Research Foundation announced a strategic collaboration to advance ART-101, a next-generation PSMA-targeting radiopharmaceutical, into clinical development with Phase 1 trials planned for 2025.

Scientists have developed a revolutionary bioprinter that uses ultrasound technology to create tissues, biosensors, and medication depots deep within the body without requiring surgical intervention.

A large clinical trial published in JAMA Network Open demonstrates that both mindfulness meditation and cognitive-behavioral therapy significantly reduced pain in patients with chronic low back pain severe enough to require opioid treatment.

The BEST-ICU trial, funded by NIH Collaboratory and NHLBI, investigates behavioral economics-based strategies to improve adoption of the evidence-based ABCDEF bundle in intensive care units.

A new study reveals that short-term hormone replacement therapy (HRT) for menopausal symptoms does not negatively impact cognitive function in women over the long term.

The NIH is investing $30 million to launch the CARE for Health network, aimed at integrating clinical research with community-based primary care.

The AVMA Veterinary Clinical Trials Registry lists studies for animal health, connecting researchers with veterinarians and owners.

A recent study estimates that 5.1 to 5.6 million Americans with depression could be eligible for psilocybin-assisted therapy if approved by the FDA.